BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Kabolowsky M, Nguyen L, Fortune BE, Santos E, Kishore S, Camacho JC. Interventional Management of Portal Hypertension in Cancer Patients. Curr Oncol Rep 2022. [PMID: 35953600 DOI: 10.1007/s11912-022-01319-8] [Reference Citation Analysis]
2 Yan XH, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, Meng MM, Zhang K, Jiang L, Ding HG, Zhang YN, Yang YP, Liu FQ. Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension. World J Gastrointest Surg 2022; 14(6): 567-579 [DOI: 10.4240/wjgs.v14.i6.567] [Reference Citation Analysis]
3 Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Reference Citation Analysis]
4 Akash Shukla, Patkar S, Sundaram S, Shah SR, Ingle M, Gupta A, Gopan A, Kamat M, Mohanka R, Singh S, Walke S, Pandey V, Goel M. CLINICAL PROFILE, PATTERNS OF CARE & ADHERENCE TO GUIDELINES IN PATIENTS WITH HEPATOCELLULAR CANCER: PROSPECTIVE MULTI-CENTER STUDY. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.05.006] [Reference Citation Analysis]
5 Kim J, Byun HK, Kim TH, Kim SI, Kim BK, Kim SU, Park JY, Kim DY, Seong J. Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2022;14:2396. [PMID: 35626001 DOI: 10.3390/cancers14102396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
7 Chen CL, Ong AD, Cheng JY, Yong CC, Lin CC, Chen CY, Cheng YF. Proton beam therapy to bridge or downstage locally advanced hepatocellular carcinoma to living donor liver transplantation. Hepatobiliary Surg Nutr 2022;11:103-11. [PMID: 35284524 DOI: 10.21037/hbsn-21-379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mo Z, Ding H, Zhou X, Zeng Z, Long L. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1. Abdom Radiol (NY) 2022;47:209-20. [PMID: 34738148 DOI: 10.1007/s00261-021-03325-z] [Reference Citation Analysis]
9 Feng X, Jiang T, Yang C, Pang S, Ding Z, Hu H, Wang H, Dong L, Yang N. RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. Cell Death Dis 2021;13:6. [PMID: 34921137 DOI: 10.1038/s41419-021-04447-4] [Reference Citation Analysis]
10 Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00229-0. [PMID: 34955380 DOI: 10.1016/j.hbpd.2021.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Abulimiti M, Li Z, Wang H, Apiziaji P, Abulimiti Y, Tan Y. Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. J Oncol 2021;2021:9943683. [PMID: 34899910 DOI: 10.1155/2021/9943683] [Reference Citation Analysis]
12 Patidar Y, Chandel K, Condati NK, Srinivasan SV, Mukund A, Sarin SK. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma – A Retrospective Study. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.12.009] [Reference Citation Analysis]
13 Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY) 2021;46:5723-34. [PMID: 34519877 DOI: 10.1007/s00261-021-03270-x] [Reference Citation Analysis]
14 Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:5162-79. [PMID: 34410432 DOI: 10.1007/s00261-021-03248-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Reference Citation Analysis]
16 Dutta D, Tatineni T, Yarlagadda S, Gupte A, Reddy SK, Madhavan R, Nair H, Sasidharan A, Kannan R, Pottayil SG, Holla R, Sudhindran S. Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study. Indian J Gastroenterol 2021;40:389-401. [PMID: 34694581 DOI: 10.1007/s12664-021-01172-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Liu J, Ladbury C, Amini A, Glaser S, Kessler J, Lee A, Chen YJ. Combination of yttrium-90 radioembolization with stereotactic body radiation therapy in the treatment of portal vein tumor thrombosis. Radiat Oncol J 2021;39:113-21. [PMID: 34619828 DOI: 10.3857/roj.2021.00213] [Reference Citation Analysis]
18 Yang DS, Park S, Rim CH, Yoon WS, Shin IS, Lee HA. Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Medicina (Kaunas) 2021;57:1000. [PMID: 34684036 DOI: 10.3390/medicina57101000] [Reference Citation Analysis]
19 Sadiq AM, Mashonganyika TJ, Mmbaga LG, Sadiq AM, Nkya GZ. Hepatocellular carcinoma in a non-cirrhotic liver with a tumor thrombus. Clin Case Rep 2021;9:e04800. [PMID: 34512986 DOI: 10.1002/ccr3.4800] [Reference Citation Analysis]
20 Lee SJ, Kim M, Kwak YK, Kang HJ. MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety. J Cancer Res Clin Oncol 2021. [PMID: 34490584 DOI: 10.1007/s00432-021-03788-z] [Reference Citation Analysis]
21 Cao Y, Sun T, Guo X, Ouyang T, Kan X, Chen L, Liang B, Wang M, Zheng C. Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study. Front Oncol 2021;11:673378. [PMID: 34414104 DOI: 10.3389/fonc.2021.673378] [Reference Citation Analysis]
22 Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Front Oncol 2021;11:650394. [PMID: 34408974 DOI: 10.3389/fonc.2021.650394] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Arora S, Harmath C, Catania R, Mandler A, Fowler KJ, Borhani AA. Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings. Abdom Radiol (NY) 2021;46:3698-707. [PMID: 34091729 DOI: 10.1007/s00261-021-03151-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nevarez NM, Yopp AC. Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Hepatocell Carcinoma 2021;8:851-60. [PMID: 34350140 DOI: 10.2147/JHC.S291530] [Reference Citation Analysis]
25 Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatol Res 2021;51:979-89. [PMID: 34245216 DOI: 10.1111/hepr.13693] [Reference Citation Analysis]
26 Li X, Ye Z, Lin S, Pang H. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer 2021;21:701. [PMID: 34126955 DOI: 10.1186/s12885-021-08469-1] [Reference Citation Analysis]
27 Glantzounis GK, Karampa A, Peristeri DV, Pappas-Gogos G, Tepelenis K, Tzimas P, Cyrochristos DJ. Recent advances in the surgical management of hepatocellular carcinoma. Ann Gastroenterol 2021;34:453-65. [PMID: 34276183 DOI: 10.20524/aog.2021.0632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Shehta A, Farouk A, Elghawalby AN, Elshobary M, Aboelenin A, Fouad A, Ali MA. Outcomes of Hepatic Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. J Surg Res 2021;266:269-83. [PMID: 34038849 DOI: 10.1016/j.jss.2021.04.011] [Reference Citation Analysis]
29 Handa S, Gupta K, Sterpi M, Khan A, Hoskote A, Kasi A. Trends and In-Hospital Outcomes of Splanchnic Vein Thrombosis Associated with Gastrointestinal Malignancies: A Nationwide Analysis. Gastrointest Tumors 2021;8:71-80. [PMID: 33981685 DOI: 10.1159/000513368] [Reference Citation Analysis]
30 Li J, Zhu D, Ma W, Yang Y, Wang G, Wu X, Wang K, Chen Y, Wang F, Liu W, Yuan Y. Rapid synthesis of a Bi@ZIF-8 composite nanomaterial as a near-infrared-II (NIR-II) photothermal agent for the low-temperature photothermal therapy of hepatocellular carcinoma. Nanoscale 2020;12:17064-73. [PMID: 32785323 DOI: 10.1039/d0nr03907a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 14.0] [Reference Citation Analysis]
31 Aydin C, Yilmaz S. Is Macroscopic Portal Vein Tumor Thrombosis of HCC Really an Exclusion for Liver Transplantation? J Gastrointest Cancer 2020;51:1137-40. [PMID: 32833219 DOI: 10.1007/s12029-020-00488-8] [Reference Citation Analysis]
32 Ma E, Li J, Xing H, Li R, Shen C, Zhang Q, Ma Z, Tao Y, Qin L, Zhao J, Wang Z. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann Transl Med 2021;9:468. [PMID: 33850865 DOI: 10.21037/atm-21-334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Tsai HM, Han MZ, Lin YJ, Chang TT, Chen CY, Cheng PN, Chuang CH, Wu IC, Chen PJ, Kang JW, Chiu YC, Chiu HC, Chien SC, Kuo HY. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunol Immunother 2021;70:1929-37. [PMID: 33409737 DOI: 10.1007/s00262-020-02845-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Villalobos A, Soliman MM, Majdalany BS, Schuster DM, Galt J, Bercu ZL, Kokabi N. Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. Semin Intervent Radiol 2020;37:543-54. [PMID: 33328711 DOI: 10.1055/s-0040-1720954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 LeGout JD, Bailey RE, Bolan CW, Bowman AW, Chen F, Cernigliaro JG, Alexander LF. Multimodality Imaging of Abdominopelvic Tumors with Venous Invasion. Radiographics 2020;40:2098-116. [PMID: 33064623 DOI: 10.1148/rg.2020200047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. Cardiovasc Intervent Radiol 2021;44:63-72. [PMID: 32965582 DOI: 10.1007/s00270-020-02579-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Kang K, Song SK, Chung CW, Park Y. Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies. Ann Hepatobiliary Pancreat Surg 2020;24:243-51. [PMID: 32843588 DOI: 10.14701/ahbps.2020.24.3.243] [Reference Citation Analysis]
38 Zheng R, Zhu HL, Hu BR, Ruan XJ, Cai HJ. Identification of APEX2 as an oncogene in liver cancer. World J Clin Cases 2020; 8(14): 2917-2929 [PMID: 32775374 DOI: 10.12998/wjcc.v8.i14.2917] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
39 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the standard indications. Med Oncol 2020;37:23. [PMID: 32166482 DOI: 10.1007/s12032-020-01348-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]